Important Notice

You are now leaving the Averitas Pharma, Inc. website and will be redirected to a site intended for an international audience. Please be aware that the content, products, and services on the international site may differ from those on our U.S. site and may not be approved for a U.S. audience.

Click "Continue" if you wish to proceed to the international site, or "Cancel" to stay on the current page.

‘Sensory’ Science

Research based on finding new therapeutic targets for the treatment of several diseases and the pain associated with them has led to the discovery of various molecular regulators of ion channels that are found in neurons and whose activation will result in pain.

A gateway to understanding pain

The transient receptor potential vanilloid 1 (TRPV1) channel is located in sensory neurons throughout the body and responds to noxious or harmful stimuli.

An emerging therapeutic target

TRPV1 has been associated with several pathophysiological conditions, including diabetic neuropathy, postherpetic neuralgia, post-surgical neuropathic pain and osteoarthritis.

Building on the science

We are leveraging the discovery of this pathway to develop TRPV1 agonists that desensitize nerves via a process called neuronal ‘defunctionalization.’


This figure contains information about ongoing studies of investigational products and uses which are not approved by the US FDA, and the safety and efficacy of these investigational products and uses have not been established.

*Collaboration with Mesoblast Ltd.